Seeking to change lives with next generation peptide therapeutics
Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism
Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)
Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions
Upcoming events
Share Price
Our research
Applying our peptide platform to specialty disease areas to invent novel therapies.
Read more
Late-stage pipeline
Advancing fully owned development programs with Phase 3 in two rare disease programs. See our pipeline
About Zealand
Get a brief overview on Zealand and learn more about our company. Read more
Investors
Information for analysts, investors, and shareholders.
Read more